BioSpace News Archive

Eliem Therapeutics, Inc., a company delivering therapies that empower patients to live on their own terms, officially launched with $80 million in financing since its inception in 2019.

Coherent, Inc. announced that its board of directors has determined, after consultation with its financial and legal advisors, that the previously disclosed acquisition proposal Coherent received from II-VI Incorporated on March 17, 2021 continues to be a “Company Superior Proposal” under Coherent’s March 9, 2021 merger agreement with Lumentum Holdings Inc. after giving due consideration to the revised acquisition proposal Coherent received from Lumentum on March 22, 2021.

Strong financial performance and the achievement of other key milestones demonstrate the growing strength of Synthace’s offering within the biopharma and biotech industries.

Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline

As the first baby boomers reach their 75th birthday this year, a new study commissioned by the Canadian Medical Association estimates the cost and demand for elder care will nearly double by 2031.

The German brand Alcovit has created a product that addresses the hangover in an innovative fashion.

NeurOptics, the leader in the science of pupillometry, recently announced that its NPi®-200 pupillometers and the Neurological Pupil Index™ (NPi®) are now being used in the Neurological Intensive Care Unit at Vanderbilt University Medical Center, a highly acclaimed teaching hospital in Nashville, Tenn., as an important measurement for managing patients with brain injury.

CARICOM is an organization of 15 states, five associate members and other participants throughout the Caribbean with the primary objectives to promote economic integration and cooperation among its members.

Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab).

Gilde Healthcare, a specialized healthcare investor with $1.8 billion under management, announced that its portfolio company, LAVA Therapeutics, has successfully achieved pricing of its Nasdaq initial public offering, expected to result in gross proceeds of approximately $100 million.